Voyager Therapeutics, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Voyager Therapeutics, Inc. (VYGR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $276.00 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2018-11-07
- Voyager Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2018-09-30 was $69.00M, a 45.26% increase year-over-year.
- Voyager Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-12-31 was $37.50M, a 5.93% increase year-over-year.
- Voyager Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-09-30 was $47.50M, a 23.01% decline year-over-year.
- Voyager Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-06-30 was $39.00M, a 29.09% decline year-over-year.
- Voyager Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $147.60M, a 10.60% decline from fiscal 2016.
- Voyager Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $165.10M, a 519.28% increase from fiscal 2015.
- Voyager Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2015 was $26.66M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2018-09-30 | $69.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $276.00M 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | $207.00M 10-Q · filed 2018-08-07 | |||
| 2017-12-31 | $37.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $85.00M derived: sum of 2 quarters · filed 2018-11-07 | $124.00M derived: sum of 3 quarters · filed 2018-11-07 | $147.60M 10-K · filed 2018-03-14 |
| 2017-09-30 | $47.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $86.50M derived: sum of 2 quarters · filed 2018-11-07 | $110.10M 10-Q · filed 2018-11-07 | $145.50M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $39.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $62.60M 10-Q · filed 2018-08-07 | $98.00M derived: sum of 3 quarters · filed 2018-08-07 | $159.70M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $23.60M 10-Q · filed 2017-05-09 | $59.00M derived: sum of 2 quarters · filed 2018-03-14 | $120.70M derived: sum of 3 quarters · filed 2018-03-14 | $175.70M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-12-31 | $35.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $97.10M derived: sum of 2 quarters · filed 2018-03-14 | $152.10M derived: sum of 3 quarters · filed 2018-03-14 | $165.10M 10-K · filed 2018-03-14 |
| 2016-09-30 | $61.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $116.70M derived: sum of 2 quarters · filed 2017-11-02 | $129.70M 10-Q · filed 2017-11-02 | $150.36M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $55.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $68.00M 10-Q · filed 2017-08-08 | $88.66M derived: sum of 3 quarters · filed 2018-03-14 | $90.66M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $13.00M 10-Q · filed 2017-05-09 | $33.66M derived: sum of 2 quarters · filed 2018-03-14 | $35.66M derived: sum of 3 quarters · filed 2018-03-14 | |
| 2015-12-31 | $20.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $22.66M derived: sum of 2 quarters · filed 2018-03-14 | $26.66M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $6.00M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $4.00M 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |